Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of PM Modulation Therapy in Trial Phase

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03110601
Recruitment Status : Completed
First Posted : April 12, 2017
Results First Posted : April 16, 2019
Last Update Posted : April 16, 2019
Sponsor:
Information provided by (Responsible Party):
Stimgenics LLC

Brief Summary:
Trialing of PM modulation therapy in patients with chronic intractable low back pain

Condition or disease Intervention/treatment Phase
Chronic Pain Device: Control - Conventional SCS Device: Test - Stimgenics SCS Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Trialing of PM Modulation Therapy in Patients With Chronic Intractable Low Back Pain With or Without Leg Pain
Actual Study Start Date : May 5, 2017
Actual Primary Completion Date : October 12, 2017
Actual Study Completion Date : October 12, 2017

Arm Intervention/treatment
Active Comparator: Control - Conventional SCS
Conventional SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
Device: Control - Conventional SCS
Conventional SCS Parameters

No Intervention: Washout Period
1 day where no stimulation is provided
Experimental: Test - Stimgenics SCS
Stimgenics SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
Device: Test - Stimgenics SCS
Stimgenics SCS Parameters




Primary Outcome Measures :
  1. Change in Pain Relative to Baseline and After a Trial Period [ Time Frame: Baseline and 4 days plus or minus 1 days ]
    Numerical rating pain score measured before and after intervention. 11-point Numeric Pain Rating Scale (NPRS) with 0 being no pain at all and 10 being the worst pain imaginable (1-3 is rated as mild pain, 4-6 is rated at moderate pain, 7-9 is rated as severe pain). Subject rates average pain for the past 7 days.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Capable of giving written informed consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the patient's participation is provided to them.
  2. Chronic intractable pain of the lower back equal to or greater than pain in lower limbs, and that has been refractory to conservative therapy for ≥ 3 months.
  3. Must be older than 18 years old.
  4. Average back pain intensity of ≥ 5 out of 10 on the numerical pain rating scale (NPRS).
  5. Appropriate candidate for spinal cord stimulation trial.
  6. Subjects must be on a stable dose of pain medication regimen for at least 1 month.
  7. Female patients who are not pregnant and do not plan to become pregnant during the study. Females of child bearing potential must provide a negative pregnancy test and must be using reliable contraception and must continue to use reliable contraception until study completion. Non-childbearing potential is defined as postmenopausal for at least 2 years or surgical sterilization or hysterectomy at least 3 months before study start. Patients who become pregnant or who have a spouse/significant other that becomes pregnant during the course of this study agree to report pregnancy to the study physician/staff.
  8. Must be able to comply with the requirement of study visits and follow-up and phone visits.
  9. Have cognitive ability of operate the remote control and follow therapy instructions and directions by clinicians.

Exclusion Criteria:

  1. Systemic infection.
  2. Any active implanted device.
  3. Previous experience with SCS therapy either during a trial or fully implanted
  4. Evidence of serious neurological, psychological or psychiatric disorders.
  5. Mechanical spinal instability.
  6. Patients with uncorrected coagulation disorders or who are on anticoagulation therapy and cannot interrupt the therapy.
  7. Patient who are pregnant, breast-feeding or women of childbearing potential with positive pregnancy tests.
  8. Human immunodeficiency virus (HIV) infection or a clinically significant infection.
  9. Patients who are undergoing or will undergo therapies or diagnostics that involve electromagnetic fields such as: diathermy based therapies, electrocautery, magnetic resonance imaging (MRI), radiofrequency (RF) or microwave ablation, bone growth stimulators, electrolysis, therapeutic ultrasound, ultrasound, lithotripsy, psychotherapeutic procedures, radiation therapy, and transcutaneous electrical nerve stimulation.
  10. A clinically significant disorder such as cerebrovascular disease, pulmonary infarction, ischemic heart disease, cardiac dysrhythmia, myocardial infarction, or congestive heart failure or any other as determined by the investigator.
  11. Uncontrolled diabetes, uncontrolled pulmonary disease, or uncontrolled hypertension.
  12. Patients who have evidence of major psychiatric disease, mental disorder, drug dependency, alcohol dependency, or substance abuse disorders.
  13. Patients who have progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, acute herniated disc, or any other as determined by investigator.
  14. Medical condition or pain in other body areas that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study end points.
  15. Concurrent participation in another clinical study.
  16. Involvement in an injury claim under current litigation or a pending or approved workers' compensation claim.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03110601


Locations
Layout table for location information
United States, Illinois
StimGenics
Bloomington, Illinois, United States, 61701
Sponsors and Collaborators
Stimgenics LLC
  Study Documents (Full-Text)

Documents provided by Stimgenics LLC:
Layout table for additonal information
Responsible Party: Stimgenics LLC
ClinicalTrials.gov Identifier: NCT03110601    
Other Study ID Numbers: SGEN-2017PM1
First Posted: April 12, 2017    Key Record Dates
Results First Posted: April 16, 2019
Last Update Posted: April 16, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Pain
Pain
Neurologic Manifestations